Advertisement

European Radiology

, Volume 27, Issue 7, pp 3022–3032 | Cite as

Prognostic relevance of gemistocytic grade II astrocytoma: gemistocytic component and MR imaging features compared to non-gemistocytic grade II astrocytoma

  • Young Jin Heo
  • Ji Eun Park
  • Ho Sung Kim
  • Ji Ye Lee
  • Soo Jeong Nam
  • Seung Chai Jung
  • Choong Gon Choi
  • Sang Joon Kim
Magnetic Resonance

Abstract

Objectives

To determine if gemistocytic grade II astrocytoma (GemA) and its MR imaging characteristics are associated with a shorter time-to-progression (TTP) compared with non-gemistocytic grade II astrocytoma (non-GemA).

Materials and methods

We enrolled 78 patients who were followed up more than 5 years (29 pathologically proven GemA and 49 non-GemA) during a 10-year period. Contrast-enhanced T1-weighted, diffusion-weighted imaging (DWI), dynamic susceptibility contrast (DSC), and MR spectroscopy (MRS) and clinical data were retrospectively reviewed. Clinical and MR imaging features were analyzed as possible prognostic factors of high-grade transformation, and multivariate analysis of TTP was performed using Cox proportional modeling.

Results

GemA showed more frequent high-grade features than non-GemA, including diffusion restriction (P < .001), increased choline/creatine (P = .02), and increased choline/NAA ratio (P = .015). Patients with GemA had a significantly shorter median TTP (53.1 vs 68 months; P < .001). A gemistocytic histopathology (hazard ratio = 3.42; P = .015) and low ADC (hazard ratio = 3.61; P = .001) were independently associated with a shorter TTP.

Conclusions

GemA can present with MR imaging findings mimicking high-grade glioma at initial diagnosis and transforms to high-grade disease earlier than non-GemA. Low ADC on DWI might be useful in stratifying the risk of progression in patients with grade II astrocytoma.

Key Points

Gemistocytic grade II astrocytoma (GemA) showed more frequent high-grade features than non-GemA.

Patients with GemA had a significantly shorter median TTP than non-GemA.

Gemistocytic histopathology and low ADC were independently associated with shorter TTP.

Keywords

Astrocytoma Grade II Gemistocytic astrocytoma Disease progression Diffusion magnetic resonance imaging 

Abbreviations

GemA

Gemistocytic low-grade astrocytoma

non-GemA

Non-gemistocytic low-grade astrocytoma

DWI

Diffusion-weighted imaging

DSC

Dynamic susceptibility contrast

MRS

MR spectroscopy

TTP

Time-to-progression

ADC

Apparent diffusion coefficient

nCBV

Normalized cerebral blood volume

Notes

Acknowledgments

The scientific guarantor of this publication is Sang Joon Kim. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (grant number: NRF-2014R1A2A2A01004937). No complex statistical methods were necessary for this paper. Institutional Review Board approval was obtained. Written informed consent was waived by the Institutional Review Board. Methodology: retrospective, observational study, performed at one institution.

Supplementary material

330_2016_4649_MOESM1_ESM.docx (14 kb)
ESM 1 (DOCX 13 kb)

References

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Krouwer HG, Davis RL, Silver P, Prados M (1991) Gemistocytic astrocytomas: a reappraisal. J Neurosurg 74:399–406CrossRefPubMedGoogle Scholar
  3. 3.
    Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumours of the Central Nervous System: a summary. Acta Neuropathol 131:803–820CrossRefPubMedGoogle Scholar
  4. 4.
    Schomas DA, Laack NNI, Rao RD et al (2009) Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro-Oncology 11:437–445CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Smith JS, Chang EF, Lamborn KR et al (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:1338–1345CrossRefPubMedGoogle Scholar
  6. 6.
    Babu R, Bagley JH, Park JG, Friedman AH, Adamson C (2013) Low-grade astrocytomas: the prognostic value of fibrillary, gemistocytic, and protoplasmic tumour histology: clinical article. J Neurosurg 119:434–441CrossRefPubMedGoogle Scholar
  7. 7.
    Okamoto Y, Di Patre PL, Burkhard C et al (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56CrossRefPubMedGoogle Scholar
  8. 8.
    Russel D, Rubinstein L (1989) Pathology of tumours of the central nervous systemGoogle Scholar
  9. 9.
    Tihan T, Vohra P, Berger MS, Keles GE (2006) Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective. J Neuro-Oncol 76:175–183CrossRefGoogle Scholar
  10. 10.
    Wang Q, Zhang H, Zhang J et al (2016) The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: a systematic review and meta-analysis. Eur Radiol 26:2670–2684CrossRefPubMedGoogle Scholar
  11. 11.
    Togao O, Hiwatashi A, Yamashita K et al (2016) Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion- and perfusion-weighted imaging. Eur RadiolGoogle Scholar
  12. 12.
    Abe K, Hasegawa H, Kobayashi Y, Fujimura H, Yorifuji S, Bitoh S (1990) A gemistocytic astrocytoma demonstrated high intensity on MR images. Neuroradiology 32:166–167CrossRefPubMedGoogle Scholar
  13. 13.
    Godefroy A, Derrey S, Laquerriere A, Perot G, Proust F, Gerardin E (2012) Perfusion MR imaging and MR spectroscopy of gemistocytic astrocytoma. J Neuroradiol 39:190–194CrossRefPubMedGoogle Scholar
  14. 14.
    Kleihues P, Louis DN, Scheithauer BW et al (2002) The WHO classification of tumours of the nervous system. J Neuropathol Exp Neurol 61:215–225CrossRefPubMedGoogle Scholar
  15. 15.
    van den Bent MJ, Wefel JS, Schiff D et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12:583–593CrossRefPubMedGoogle Scholar
  16. 16.
    Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMedGoogle Scholar
  17. 17.
    Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumour grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27:859–867PubMedGoogle Scholar
  18. 18.
    Seo N, Park SH, Kim KJ et al (2016) MR enterography for the evaluation of small-bowel inflammation in Crohn disease by using diffusion-weighted Imaging without intravenous contrast material: a prospective noninferiority study. Radiology 278:762–772CrossRefPubMedGoogle Scholar
  19. 19.
    Hoshino T, Wilson BC, Ellis WG (1975) Gemistocytic astrocytes in gliomas. An autoradiographic study. J Neuropathol Exp Neurol 34:263–281CrossRefPubMedGoogle Scholar
  20. 20.
    Yang H, Kim J, Paek S, Chi J, Jung H-W, Kim D (2003) The significance of gemistocytes in astrocytoma. Acta Neurochir 145:1097–1103CrossRefPubMedGoogle Scholar
  21. 21.
    Kreth FW, Faist M, Rossner R, Volk B, Ostertag CB (1997) Supratentorial World Health Organization grade 2 astrocytomas and oligoastrocytomas. Cancer 79:370–379CrossRefPubMedGoogle Scholar
  22. 22.
    Kreth FW, Faist M, Warnke PC, Roβner R, Volk B, Ostertag CB (1995) Interstitial radiosurgery of low-grade gliomas. J Neurosurg 82:418–429CrossRefPubMedGoogle Scholar
  23. 23.
    Miller CR, Perry A (2007) Morphologic and molecular genetic diversity. Arch Pathol Lab Med 131:397–406PubMedGoogle Scholar
  24. 24.
    Xiao HF, Chen ZY, Lou X et al (2015) Astrocytic tumour grading: a comparative study of three-dimensional pseudocontinuous arterial spin labelling, dynamic susceptibility contrast-enhanced perfusion-weighted imaging, and diffusion-weighted imaging. Eur Radiol 25:3423–3430CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Murakami R, Sugahara T, Nakamura H et al (2007) Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 243:493–499CrossRefPubMedGoogle Scholar
  26. 26.
    Pope WB, Kim HJ, Huo J et al (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252:182–189CrossRefPubMedGoogle Scholar
  27. 27.
    Tomura N, Narita K, Izumi J et al (2006) Diffusion changes in a tumour and peritumoural tissue after stereotactic irradiation for brain tumours: possible prediction of treatment response. J Comput Assist Tomogr 30:496–500CrossRefPubMedGoogle Scholar
  28. 28.
    Zulfiqar M, Yousem DM, Lai H (2013) ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumour?—A meta-analysis. Am J Roentgenol 200:624–629CrossRefGoogle Scholar
  29. 29.
    Caseiras GB, Ciccarelli O, Altmann DR et al (2009) Low-grade gliomas: six-month tumour growth predicts patient outcome better than admission tumour volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology 253:505–512CrossRefGoogle Scholar
  30. 30.
    Wessels PH, Weber WE, Raven G, Ramaekers F, Hopman AH, Twijnstra A (2003) Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2:395–403CrossRefPubMedGoogle Scholar

Copyright information

© European Society of Radiology 2016

Authors and Affiliations

  1. 1.Department of RadiologyInje University, Busan Paik HospitalBusanKorea
  2. 2.Department of Radiology and Research Institute of RadiologyUniversity of Ulsan College of Medicine, Asan Medical CenterSeoulKorea
  3. 3.Department of PathologyUniversity of Ulsan College of Medicine, Asan Medical CenterSeoulKorea

Personalised recommendations